Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who Wants To Be 'Essential'? US FDA Considers Critical Drugs List

Executive Summary

To address chronic shortages, FDA may create list of 'essential' drugs, but will suppliers of those products be happy to be designated 'essential'? 

You may also be interested in...



New AAM CEO: Traditional Lobbying On Lowering Health Care Costs Can Mix With COVID-19 Talks

Dan Leonard is working on post-pandemic generic drug issues, using coronavirus as a way to get in front of lawmakers.

AAM Offers Drug Manufacturing Repatriation Plan … For A Price

Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.

Drug Shortages: Would Sponsors Admit Their Products Are Vulnerable?

US FDA's upcoming drug shortage risk criteria will be made public and sponsors could be asked to find the vulnerable products in their portfolios.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel